TABLE 2.
Treatment‐emergent adverse events as n (%)
| Adverse event | Study 1 (Overweight/Obese) | Study 2 (T1D) | ||
|---|---|---|---|---|
|
Eptinezumab 100 mg N = 16 |
Placebo N = 8 |
Eptinezumab 100 mg N = 14 |
Placebo N = 7 |
|
| Any TEAE | 6 (37.5) | 2 (25.0) | 12 (85.7) | 7 (100.0) |
| Serious TEAE | 0 | 0 | 0 | 0 |
| Study drug‐related TEAE | 1 (6.3) | 0 | 2 (14.3) | 2 (28.6) |
| TEAE leading to study discontinuation | 0 | 0 | 0 | 0 |
| Most common events (≥2 patients in any treatment group) | ||||
| Hypoglycaemia | 0 | 0 | 10 (71.4) | 4 (57.1) |
| URTI | 1 (6.3) | 1 (12.5) | 2 (14.3) | 3 (42.9) |
| Abdominal pain | 1 (6.3) | 0 | 0 | 2 (28.6) |
| Diarrhoea | 0 | 0 | 0 | 2 (28.6) |
Abbreviations: T1D, type 1 diabetes; TEAE, treatment‐emergent adverse event; URTI, upper respiratory tract infection.